Nabumetone: a double-blind study in osteoarthrosis.
A double-blind, placebo-controlled, crossover trial was carried out to assess the efficacy and tolerance of nabumetone in patients with osteoarthrosis of the hip or knee. Patients were allocated at random to receive either 1 g nabumetone twice daily or matching placebo for 2 weeks and then crossed over to the alternative treatment for a further 2 weeks. Clinical assessments of pain and function were made before and at the end of each treatment period. Seventeen of 18 patients completed the trial and the results showed that most clinical parameters assessed were improved during active treatment, with significantly more patients preferring nabumetone (p less than 0.001) to placebo. Only 1 patient reported what was considered to be a drug-related adverse event (irritation of the scalp) during nabumetone treatment.
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002074:Butanones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy*; D010919:Placebos; D011897:Random Allocation; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D002074:Butanones; D010919:Placebos; D000077430:Nabumetone